144 related articles for article (PubMed ID: 35068557)
21. Development of hot melt co-formulated antimalarial solid dispersion system in fixed dose form (ARLUMELT): Evaluating amorphous state and in vivo performance.
Fule R; Dhamecha D; Maniruzzaman M; Khale A; Amin P
Int J Pharm; 2015 Dec; 496(1):137-56. PubMed ID: 26471056
[TBL] [Abstract][Full Text] [Related]
22. The Preparation of Curcumin Sustained-Release Solid Dispersion by Hot-Melt Extrusion-Ⅱ. Optimization of Preparation Process and Evaluation In Vitro and In Vivo.
Fan W; Zhang X; Zhu W; Di L
J Pharm Sci; 2020 Mar; 109(3):1253-1260. PubMed ID: 31794699
[TBL] [Abstract][Full Text] [Related]
23. Optimization of amorphous solid dispersion techniques to enhance solubility of febuxostat.
Patel VP; Patel AP; Shah A
Folia Med (Plovdiv); 2021 Aug; 63(4):557-568. PubMed ID: 35851176
[TBL] [Abstract][Full Text] [Related]
24. Wetting Kinetics: an Alternative Approach Towards Understanding the Enhanced Dissolution Rate for Amorphous Solid Dispersion of a Poorly Soluble Drug.
Verma S; Rudraraju VS
AAPS PharmSciTech; 2015 Oct; 16(5):1079-90. PubMed ID: 25672820
[TBL] [Abstract][Full Text] [Related]
25. Development of β-Carotene-Loaded Organogel-Based Nanoemulsion with Improved In Vitro and In Vivo Bioaccessibility.
Fan Y; Gao L; Yi J; Zhang Y; Yokoyama W
J Agric Food Chem; 2017 Aug; 65(30):6188-6194. PubMed ID: 28696684
[TBL] [Abstract][Full Text] [Related]
26. Hot Melt Extrusion: Development of an Amorphous Solid Dispersion for an Insoluble Drug from Mini-scale to Clinical Scale.
Agrawal AM; Dudhedia MS; Zimny E
AAPS PharmSciTech; 2016 Feb; 17(1):133-47. PubMed ID: 26729533
[TBL] [Abstract][Full Text] [Related]
27. The influence of liquid intake on the performance of an amorphous solid dispersion in rats.
Sironi D; Bauer-Brandl A; Brandl M; Rosenberg J; Fricker G
Eur J Pharm Biopharm; 2020 Jul; 152():296-298. PubMed ID: 32470638
[TBL] [Abstract][Full Text] [Related]
28. The Development and Optimization of Hot-Melt Extruded Amorphous Solid Dispersions Containing Rivaroxaban in Combination with Polymers.
Lee JH; Jeong HS; Jeong JW; Koo TS; Kim DK; Cho YH; Lee GW
Pharmaceutics; 2021 Mar; 13(3):. PubMed ID: 33800741
[TBL] [Abstract][Full Text] [Related]
29. Hot-melt extrudability of amorphous solid dispersions of flubendazole-copovidone: An exploratory study of the effect of drug loading and the balance of adjuvants on extrudability and dissolution.
de Assis JMC; Barbosa EJ; Bezzon VDN; Lourenço FR; Carvalho FMS; Matos JR; Araci Bou-Chacra N; Benmore CJ; Byrn SR; Costa FN; de Araujo GLB
Int J Pharm; 2022 Feb; 614():121456. PubMed ID: 35017024
[TBL] [Abstract][Full Text] [Related]
30. Oral bioavailability enhancement of β-lapachone, a poorly soluble fast crystallizer, by cocrystal, amorphous solid dispersion, and crystalline solid dispersion.
Liu C; Liu Z; Chen Y; Chen Z; Chen H; Pui Y; Qian F
Eur J Pharm Biopharm; 2018 Mar; 124():73-81. PubMed ID: 29305142
[TBL] [Abstract][Full Text] [Related]
31. Application and functional characterization of POVACOAT, a hydrophilic co-polymer poly(vinyl alcohol/acrylic acid/methyl methacrylate) as a hot-melt extrusion carrier.
Xu M; Zhang C; Luo Y; Xu L; Tao X; Wang Y; He H; Tang X
Drug Dev Ind Pharm; 2014 Jan; 40(1):126-35. PubMed ID: 23336809
[TBL] [Abstract][Full Text] [Related]
32. Application of HPMC HME polymer as hot melt extrusion carrier in carbamazepine solid dispersion.
Wu H; Liu Y; Ci T; Ke X
Drug Dev Ind Pharm; 2020 Dec; 46(12):1911-1918. PubMed ID: 32942902
[TBL] [Abstract][Full Text] [Related]
33. Application of supercritical fluid technology for solid dispersion to enhance solubility and bioavailability of poorly water-soluble drugs.
Tran P; Park JS
Int J Pharm; 2021 Dec; 610():121247. PubMed ID: 34740762
[TBL] [Abstract][Full Text] [Related]
34. Application of melt extrusion in the development of a physically and chemically stable high-energy amorphous solid dispersion of a poorly water-soluble drug.
Lakshman JP; Cao Y; Kowalski J; Serajuddin AT
Mol Pharm; 2008; 5(6):994-1002. PubMed ID: 19434852
[TBL] [Abstract][Full Text] [Related]
35. Comparison of HPMC based polymers performance as carriers for manufacture of solid dispersions using the melt extruder.
Ghosh I; Snyder J; Vippagunta R; Alvine M; Vakil R; Tong WQ; Vippagunta S
Int J Pharm; 2011 Oct; 419(1-2):12-9. PubMed ID: 21782911
[TBL] [Abstract][Full Text] [Related]
36. Effect of hydrophilic additives on the dissolution and pharmacokinetic properties of itraconazole-enteric polymer hot-melt extruded amorphous solid dispersions.
Lang B; Liu S; McGinity JW; Williams RO
Drug Dev Ind Pharm; 2016; 42(3):429-45. PubMed ID: 26355819
[TBL] [Abstract][Full Text] [Related]
37. Oral Delivery of Niclosamide as an Amorphous Solid Dispersion That Generates Amorphous Nanoparticles during Dissolution.
Jara MO; Warnken ZN; Sahakijpijarn S; Thakkar R; Kulkarni VR; Christensen DJ; Koleng JJ; Williams RO
Pharmaceutics; 2022 Nov; 14(12):. PubMed ID: 36559062
[TBL] [Abstract][Full Text] [Related]
38. Improvement of thermal and UV-light stability of β-carotene-loaded nanoemulsions by water-soluble chitosan coating.
Baek EJ; Garcia CV; Shin GH; Kim JT
Int J Biol Macromol; 2020 Dec; 165(Pt A):1156-1163. PubMed ID: 33038403
[TBL] [Abstract][Full Text] [Related]
39. Preparation of Hot-Melt Extruded Dosage Form for Enhancing Drugs Absorption Based on Computational Simulation.
Choi SM; Lee SH; Kang CY; Park JB
Pharmaceutics; 2020 Aug; 12(8):. PubMed ID: 32796665
[TBL] [Abstract][Full Text] [Related]
40. Bioavailability enhancement of itraconazole-based solid dispersions produced by hot melt extrusion in the framework of the Three Rs rule.
Thiry J; Kok MG; Collard L; Frère A; Krier F; Fillet M; Evrard B
Eur J Pharm Sci; 2017 Mar; 99():1-8. PubMed ID: 27951411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
